pre-eclamspia
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Both, normotensive and preeclamptic subjects must meet the following inclusion criteria: - Women >= 18 years old - Capable of understanding the purpose and (minimal) risks of the study, fully informed and given written informed consent (signed Informed Consent Form had been obtained) - Subjects undergoing elective caesarean section Moreover, at least 1.5 cm of tissue of both, normotensive and preeclamptic subjects, should be available for our study.
Exclusion criteria
Exclusion criteria: A potential normotensive subject who meets any of the following criteria will be excluded from participation in this study: - Admission to an Intensive Care Unit (ICU) for any reason - Subjects undergoing an emergency caesarean section A potential preeclamptic subject who meets any of the following criteria will be excluded from participation in this study: - Admission to an Intensive Care Unit (ICU) for any reason - Subjects diagnosed with the HELLP syndrome (Hemolysis, Elevated Liver enzymes and Low Platelets) - Subjects undergoing an emergency caesarean section
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endpoints: - Contractions and relaxations induced by the agonists studied. - Inhibition of these contractions and relaxations by the antagonists studied. With the current in vitro study, we hope to substantiate these target engagement biomarker models as some scientific questions remain unanswered: 1) Which vasodilatory mediators are released upon activation of TRPV1 and TRPA1 with capsaicin and cinnamaldehyde, respectively? 2) Does activation of TRPM3 by pregnenolone sulfate and/or CIM0216 induce vasodilation and if so, which mediators are involved in this response? In an attempt to answer these questions, we want to evaluate the effect of capsaicin, cinnamaldehyde, pregnenolone sulfate and CIM0216 on human dermal arteries, the vessels targeted in the biomarker models in vivo. Different experimental conditions will be applied, e.g. in the presence or absence of specific channel antagonists as well as antagonists of possible mediators involved (e.g. CGRP-, NK1-, COX-inhibitors*). | — |
Secondary
| Measure | Time frame |
|---|---|
| In addition, as an exploratory objective, we want to compare the vasodilatory responses resulting from TRPV1, TRPA1 and TRPM3 activation between dermal arteries obtained from both normotensive pregnant women and preeclamptic women undergoing a caesarean section. TRPV1 has recently been pointed out as one of the receptors dysregulated in preeclampsia [5]. Furthermore, calcitonin-gene related peptide (CGRP), a potent vasodilatory peptide and possible mediator released upon TRP activation, has been suggested to play a role in the vascular tone of the placenta. | — |
Countries
Netherlands
Outcome results
None listed